Treating human multiple myeloma U266 cells with EGCG resulted in plasma membrane lipid raft disruption via the 67-LR/acid sphingomyelinase (ASM) pathway and the elicitation of EGCG-induced cell death. The gene discussed is SMPD1; the disease is plasma cell myeloma.